Pharmacyclics, Inc.
PCYCDrugs in Pipeline
29
Phase 3 Programs
12
Upcoming Catalysts
6
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
6 upcoming, 0 past
Ibrutinib
Diffuse Large B Cell Lymphoma Relapsed
Prednisone
Chronic Graft Versus Host Disease
ofatumumab
B-cell Chronic Lymphocytic Leukemia
Motexafin Gadolinium
Brain Neoplasms
Obinutuzumab
Chronic Lymphocytic Leukemia
Venetoclax
Mantle-Cell Lymphoma
Chlorambucil
Chronic Lymphocytic Leukemia
Bendamustine
Mantle Cell Lymphoma
MGd
Metastatic Cancer
Gemcitabine
Metastatic Pancreatic Adenocarcinoma
Ibrutinib Oral Capsule
Follicular Lymphoma
Next-line ibrutinib
Chronic Lymphocytic Leukemia
PCI-32765 (Ibrutinib)
Lymphoma
Blinatumomab
Adult B Acute Lymphoblastic Leukemia
Doxorubicin
Sarcoma
Fludarabine
Chronic Lymphocytic Leukemia
Dexamethasone
Multiple Myeloma
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Chronic Lymphocytic Leukemia
Lenalidomide
Relapsed Diffuse Large B-Cell Lymphoma
PCI-24781
Lymphoma
MEDI4736
Diffuse Large B-Cell Lymphoma
everolimus
Metastatic Renal Cell Carcinoma
Motexafin Gadolinium Injection
Multiple Myeloma
PCI-27483
Pancreatic Cancer
PCI-32765
B-cell Chronic Lymphocytic Leukemia
Carfilzomib
Multiple Myeloma
Bortezomib
Multiple Myeloma
GA101
Chronic Lymphocytic Leukemia
Ibrutinib 560 mg
Breast Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ibrutinib | Phase 3 | Diffuse Large B Cell Lymphoma Relapsed | - | - |
Prednisone | Phase 3 | Chronic Graft Versus Host Disease | - | - |
ofatumumab | Phase 3 | B-cell Chronic Lymphocytic Leukemia | - | - |
Motexafin Gadolinium | Phase 3 | Brain Neoplasms | - | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Venetoclax | Phase 3 | Mantle-Cell Lymphoma | - | - |
Chlorambucil | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Bendamustine | Phase 3 | Mantle Cell Lymphoma | - | - |
MGd | Phase 3 | Metastatic Cancer | - | - |
Gemcitabine | Phase 3 | Metastatic Pancreatic Adenocarcinoma | - | - |
Ibrutinib Oral Capsule | Phase 3 | Follicular Lymphoma | - | - |
Next-line ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
PCI-32765 (Ibrutinib) | Phase 2 | Lymphoma | - | - |
Blinatumomab | Phase 2 | Adult B Acute Lymphoblastic Leukemia | - | - |
Doxorubicin | Phase 2 | Sarcoma | - | - |
Fludarabine | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Dexamethasone | Phase 2 | Multiple Myeloma | - | - |
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Lenalidomide | Phase 2 | Relapsed Diffuse Large B-Cell Lymphoma | - | - |
PCI-24781 | Phase 2 | Lymphoma | - | - |
MEDI4736 | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
everolimus | Phase 2 | Metastatic Renal Cell Carcinoma | - | - |
Motexafin Gadolinium Injection | Phase 2 | Multiple Myeloma | - | - |
PCI-27483 | Phase 2 | Pancreatic Cancer | - | - |
PCI-32765 | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
Carfilzomib | Phase 2 | Multiple Myeloma | - | - |
Bortezomib | Phase 2 | Multiple Myeloma | - | - |
GA101 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Ibrutinib 560 mg | Phase 2 | Breast Neoplasms | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pharmacyclics, Inc.'s drug pipeline?→
CatalystAlert tracks 29 drug candidates in Pharmacyclics, Inc.'s (PCYC) pipeline across Phase 3, Phase 2. Its lead program is Ibrutinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharmacyclics, Inc.'s next FDA catalyst?→
Pharmacyclics, Inc.'s (PCYC) next tracked catalyst is a Phase 2 expected September 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCYC biotech catalysts?→
Add PCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharmacyclics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.